Angiotensin receptor blockers retard the progression and fibrosis via inhibiting the viability of AGTR1+ CAFs in intrahepatic cholangiocarcinoma
Clinical and Translational Medicine · 2023-03 · 13 (3)
DOI: 10.1002/ctm2.1213 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Translational Medicine, online erschienen am 28.02.2023. Verfasst von Jian-Hui Li und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pancreato-Biliary Surgery, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China. Hauptthemen laut MEDLINE: Cancer-Associated Fibroblasts, Cholangiocarcinoma, Bile Duct Neoplasms. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Intrahepatic cholangiocarcinoma (iCCA) is a highly lethal malignancy characterized by massive fibrosis and has ineffective adjuvant therapies. Here, we demonstrate the potential of angiotensin receptor blockers (ARBs) in targeting iCCA.
Methods
Masson's trichrome staining was used to assess the effect of ARBs in iCCA specimens, CCK8 and gel contraction assays in vitro and in xenograft models in vivo. RNA‐seq and ATAC‐seq were used for mechanistic investigations.
Results
Patients with iCCA who were administered ARBs had a better prognosis and a lower proportion of tumour stroma, indicating alleviated fibrosis. The presence of AGTR1, the ARBs receptor, is associated with a poor prognosis of iCCA and is highly expressed in tumour tissues and cancer‐associated fibroblasts (CAFs). The ARBs strongly attenuated the viability of AGTR1+ CAFs in vitro and retarded tumour progression and fibrosis in xenograft models of co‐cultured CAFs and iCCA cells. Still, they did not have a significant effect on AGTR1− CAFs. Moreover, ARBs decreased the secretion of AGTR1+ CAF‐derived MFAP5 via the Hippo pathway, weakened the interaction between CAFs and iCCA cells, and impaired the aggressiveness of iCCA cells by attenuating the activation of the Notch1 pathway in iCCA cells.
Conclusions
ARBs exhibit anti‐fibrotic function by inhibiting the viability of AGTR1+ CAFs. These findings support using ARBs as a novel therapeutic option for targeting iCCA.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pancreato-Biliary Surgery, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.
- Department of Physiology, Zhongshan School of Medicine, Sun Yat-Sen University, Guangzhou, Guangdong, China.
- Lau Luen Hung Private Medical Center, Unit 3 (Surgery), The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.
- Key Laboratory of Stem Cells and Tissue Engineering, Sun Yat-sen University, Ministry of Education, Guangzhou, Guangdong, China.
Zitieren
APA
Li, J. H., Wu, X., Ni, X., Li, Y. X., Xu, L., Hao, X. Y., Zhao, W., Zhu, X. X., & Yin, X. Y. (2023). Angiotensin receptor blockers retard the progression and fibrosis via inhibiting the viability of AGTR1+ CAFs in intrahepatic cholangiocarcinoma. Clinical and Translational Medicine, 13(3). https://doi.org/10.1002/ctm2.1213
Vancouver
Li JH, Wu X, Ni X, Li YX, Xu L, Hao XY, et al. Angiotensin receptor blockers retard the progression and fibrosis via inhibiting the viability of AGTR1+ CAFs in intrahepatic cholangiocarcinoma. Clinical and Translational Medicine. 2023;13(3). doi:10.1002/ctm2.1213
BibTeX
@article{Li2023,
author = {Li, Jian-Hui and Wu, Xiao and Ni, Xuhao and Li, Ya-Xiong and Xu, Long and Hao, Xiao-Yi and Zhao, Wei and Zhu, Xiao-Xu and Yin, Xiao-Yu},
title = {Angiotensin receptor blockers retard the progression and fibrosis via inhibiting the viability of AGTR1+ CAFs in intrahepatic cholangiocarcinoma},
journal = {Clinical and Translational Medicine},
year = {2023},
volume = {13},
number = {3},
doi = {10.1002/ctm2.1213}
}
EUVIMED